A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

समान संसाधन

• A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
  द्वारा: Evens, A. M., और अन्य
  प्रकाशित: (2013)
• AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
  द्वारा: Noy, Ariela, और अन्य
  प्रकाशित: (2015)
• HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
  द्वारा: Rodrigo, J. A., और अन्य
  प्रकाशित: (2012)
• A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
  द्वारा: Mead, Graham M., और अन्य
  प्रकाशित: (2008)
• Modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression
  द्वारा: Noy, Ariela, और अन्य
  प्रकाशित: (2012)